TuHURA Biosciences, Inc. (NASDAQ:HURA) shares slid Friday. The company, a Phase 3 immuno-oncology concern developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter ended September 30, 2026.
The Company received $9.2 million in gross proceeds as of September 30, 2026, on the Parkview credit facility.
Research and development expenses were $3.7 million and $5.0 million for the 3 months ended September 30, 2026, and 2025, respectively. The decrease of $1.3 million was due to lower manufacturing costs, which are expected to resume in the next quarter with the start of the TBS-2025 clinical trial material manufacturing campaign.
Net cash outflows from operating activities were ($18.1) million and ($22.1) million for the 9 months ended September 30, 2026, and 2025, respectively.
Net cash flows from financing activities were $16.5 million and $13.4 million for the nine months ended September 30, 2026, and 2025, respectively.
HURA shares dipped five cents, or 3.5%. to $1.40.
